Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy

Phase 3RecruitingNCT06443606

Assistance Publique - Hôpitaux de Paris108 enrolled

Overview

Primary biliary cholangitis (PBC) is a rare chronic, progressive, cholestatic liver disease that leads to cirrhosis and its life-threatening complications if undertreated. Ursodeoxycholic acid (UDCA) is the standard-of-care therapy for PBC. However, patients with an inadequate biochemical response to UDCA according to the Paris-2 criteria are still at high-risk of poor clinical outcome. In this situation of biochemical resistance to UDCA, bezafibrate 400 mg/d given in association with UDCA has been shown to improve the symptoms, biochemical response (BEZURSO study), histologic features, and possibly long-term clinical outcome. However, it has been shown that even patients with an adequate response to UDCA but persistent elevation in biochemical markers of cholestasis or liver inflammation, including alkaline phosphatases (ALP), gamma-glutamyl transpeptidase (GGT), transaminases, or total bilirubin (i.e., non-optimal biochemical response) have still an increased risk of death or liver transplantation in the long term, thus defining the complete normalization of these markers as the new clinically-relevant target for PBC treatment. In parallel to these findings, bezafibrate 400 mg/d as a second-line therapy for PBC could be associated with potentially dose-related, muscle, kidney, or liver toxic effects, and whether bezafibrate 200 mg/d could have a better benefit/risk ratio in this disease-setting remains to be determined. Therefore, our aim is to evaluate the efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in PBC patients with non-optimal biochemical response to UDCA.

The study is a phase-3 multicenter, randomized, parallel-group (1:1:1), placebo-controlled trial with a 12-month, double-blind, placebo-free extension phase. It evaluates the efficacy and safety of bezafibrate 400 mg and bezafibrate 200 mg as adjunctive treatments in patients with PBC with an non-optimal biochemical response to UDCA. Treatments groups : Arm 1: Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg until 96 weeks in double blind. Arm 2: Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg until 96 weeks in double blind. Arm 3: Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg until 48 weeks in double blind. Then follow-up extension phase of bezafibrate 400 mg or bezafibrate 200 mg (second randomization) until 48 weeks in double blind. Assessement: Study visits at Inclusion, Randomisation (M0) and then every 3 months until W48 and extension until W96. In accordance with routine care, an additional follow-up is added between 108 and 120 weeks 32 sites within the French network of reference and competence centres for rare liver diseases FILFOIE will participate. No interim analysis planned. Analysis will be performed at the end of the study after data reviewed and data base locked according to the intent to treat principle.

Interventions

Bezafibrate 400 mg in addition to UDCA therapyDRUG

* Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d. * Duration 96 weeks bezfibrate/ UDCA = daily oral dose.

Bezafibrate 200 mg in addition to UDCA therapyDRUG

* Bezafibrate 200 mg and Placebo of Bezafibrate 400 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d. * Duration 96 weeks bezfibrate/ UDCA = daily oral dose.

Placebo in addition to UDCA therapyDRUG

* Placebo of Bezafibrate 400 mg and Placebo of Bezafibrate 200 mg in addition to continued UDCA at minimum dose of 12 mg/kg/d. * Duration 96 weeks placebo /UDCA = daily oral dose.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 and \< 80 years * Diagnosis of PBC based on at least 2 of the following criteria (EASL clinical practice guidelines 2017): * Elevated ALP level * Presence of antimitochondrial antibody (immunofluorescence titer ≥ 1:40 or positive antigen-specific test), specific antinuclear immunofluorescence (nuclear dots or perinuclear rims) or positive antigen-specific test for anti-gp210 or anti-Sp100 antibodies * Records of histologic features suggestive of, or compatible with PBC * UDCA therapy for the past 12 months (stable dose ≥ 12 mg/kg/d for ≥ 3 months prior to inclusion). * Non-optimal response to UDCA defined by at least one of the following criteria (ratios of absolute values to ULN rounded to the first decimal digit) observed at least 2 times at ≥ 4 weeks interval in the past 3 months, including at the inclusion visit assessment: * ALP \> 1.0 xULN * GGT \> 3.0 xULN * ALT or AST \> 1.0 xULN * Total and conjugated bilirubin \> 1.0 xULN * Women of childbearing potential must use at least one barrier contraceptive during the study and for at least 90 days after the last dose. * Affiliation to a social security system (AME excepted). * Signed informed consent. Exclusion Criteria: * Any of the following signs of advanced chronic liver disease: * Total bilirubin \> 2.0 xULN * Serum albumin \< 32 g/l * Platelet count \< 100,000/mm3 * INR \> 1.3 or prothrombin index \< 60% * Child-Pugh score B or C * MELD score ≥ 14 * History ≤ 24 months or presence of cirrhotic decompensation * Patients on the waiting list for LT * GFR estimated by CKI-EPI equation \< 60 mL/min * CPK \> 5.0 xULN * AST or ALT \> 3.0 xULN * History of LT * Autoimmune hepatitis (AIH) overlap syndrome defined by at least 2 of the following 3 criteria including the histologic one: * ALT \> 5.0 xULN * IgG \> 20 g/l or presence of anti-smooth muscle or anti-SLA antibodies * Histologic features characteristic of, or compatible with AIH * Any other chronic hepatic comorbidities (HCV, HBV, NASH, alcoholic liver disease, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, celiac disease) * Untreated hypo or hyperthyroidism (Hashimoto or Graves autoimmune thyroiditis) * Conditions that may cause non-hepatic increases in ALP (Paget's disease, osteodystrophy, hyperparathyroidism, dysglobulinemia) * Gilbert's syndrome or chronic hemolysis (hyperbilirubinemia with an unconjugated to total bilirubin ratio ≥ 75%) * History of or established or suspected hepatocellular carcinoma * History of malignancy diagnosed or treated within 2 years (recent localized treatment of squamous or non-invasive basal skin cancers is permitted) * Any severe comorbidity that may reduce life expectancy ≤ 2 years * Pregnancy or lactating * Known intolerance to bezafibrate * Known hypersensitivity to bezafibrate, any of the components of Befizal© or other fibrates * Known photosensitivity reactions or photoallergy reactions to fibrates * Patient with congenital galactosemia, glucose malabsorption, or lactase deficiency because of presence of lactose in LP tablets of bezafibrate * Participation in any other interventional study in the past 6 months * Any of the following medications used in the past 3 months before inclusion: bezafibrate, fenofibrate, ciprofibrate, gemfibrozil, obeticholic acid, budesonide, any other systemic corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, everolimus, methotrexate. * Use of statins in the month before inclusion

Outcomes

Primary Outcomes

To assess the effect of bezafibrate 200 mg and bezafibrate 400 mg versus placebo as adjunctive treatments in patients with PBC and a non-optimal response to UDCA.

Proportion of patients with a complete biochemical response defined by normal serum levels of alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), aminotransferases (AST, ALT), and total bilirubin at 48 weeks of treatment.

Time frame: Week 48

Secondary Outcomes

To compare adverse effects between groups, in particular on muscle, kidney, and liver.

Proportion of patients with serious adverse events (SAE) and/or adverse events (AE) at W48 and W96 (extension phase), including creatinine \> 150 μmol/L, CPK \> 10 xULN, or ALT \> 5 xULN.

Time frame: Week 48 and Week 96 ( extension phase)

To compare symptoms (Pruritus) between groups

Proportion of patients with significant pruritus based on worst itch numerical rating scale (WI-NRS).